The Saudi FDA drug evaluation timeline in comparison with international counterparts: a retrospective observational study
SFDA's review timelines align with major regulatory agencies, supporting timely drug access. Further investigation into submission patterns and regulatory challenges may improve approval rates, especially for advanced therapies.
Authors
- Aljoharah Algabbani (ORCID: https://orcid.org/0000-0002-4785-3807)
- Radwan Hafiz (ORCID: https://orcid.org/0000-0003-3010-0232)
- Bassam AlWon
Publication Details
- Journal
- Journal of Pharmaceutical Policy and Practice
- Published
- 2026-01-22
- DOI
- https://doi.org/10.1080/20523211.2025.2605398
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 0.00